These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 36495689)

  • 21. Clinical trio genome sequencing facilitates the interpretation of variants in cancer predisposition genes in paediatric tumour patients.
    Schroeder C; Faust U; Krauße L; Liebmann A; Abele M; Demidov G; Schütz L; Kelemen O; Pohle A; Gauß S; Sturm M; Roggia C; Streiter M; Buchert R; Armenau-Ebinger S; Nann D; Beschorner R; Handgretinger R; Ebinger M; Lang P; Holzer U; Skokowa J; Ossowski S; Haack TB; Mau-Holzmann UA; Dufke A; Riess O; Brecht IB
    Eur J Hum Genet; 2023 Oct; 31(10):1139-1146. PubMed ID: 37507557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.
    Hoyer J; Vasileiou G; Uebe S; Wunderle M; Kraus C; Fasching PA; Thiel CT; Hartmann A; Beckmann MW; Lux MP; Reis A
    BMC Cancer; 2018 Sep; 18(1):926. PubMed ID: 30257646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rare germline variants in childhood cancer patients suspected of genetic predisposition to cancer.
    Sylvester DE; Chen Y; Grima N; Saletta F; Padhye B; Bennetts B; Wright D; Krivanek M; Graf N; Zhou L; Catchpoole D; Kirk J; Latchoumanin O; Qiao L; Ballinger M; Thomas D; Jamieson R; Dalla-Pozza L; Byrne JA
    Genes Chromosomes Cancer; 2022 Feb; 61(2):81-93. PubMed ID: 34687117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Germline potential should not be overlooked for cancer variants identified in tumour-only somatic mutation testing.
    Al-Shinnag M; Cheong PL; Goodwin A; Trent R; Yu B
    Pathology; 2024 Jun; 56(4):468-472. PubMed ID: 38627125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of germline variants in Brazilian breast cancer patients using multigene panel testing.
    Guindalini RSC; Viana DV; Kitajima JPFW; Rocha VM; López RVM; Zheng Y; Freitas É; Monteiro FPM; Valim A; Schlesinger D; Kok F; Olopade OI; Folgueira MAAK
    Sci Rep; 2022 Mar; 12(1):4190. PubMed ID: 35264596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.
    Batalini F; Peacock EG; Stobie L; Robertson A; Garber J; Weitzel JN; Tung NM
    Breast Cancer Res; 2019 Sep; 21(1):107. PubMed ID: 31533767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paired tumor sequencing and germline testing in breast cancer management: An experience of a single academic center.
    Elliott E; Speare V; Coggan J; Espenschied C; LaDuca H; Yussuf AF; Burgess K; Gray P; Cobleigh M; Rao R; Patel J; Kuzel T; Buckingham LE; Usha L
    Cancer Rep (Hoboken); 2020 Dec; 3(6):e1287. PubMed ID: 32881420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
    Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic Implications of Germline Testing in Patients With Advanced Cancers.
    Stadler ZK; Maio A; Chakravarty D; Kemel Y; Sheehan M; Salo-Mullen E; Tkachuk K; Fong CJ; Nguyen B; Erakky A; Cadoo K; Liu Y; Carlo MI; Latham A; Zhang H; Kundra R; Smith S; Galle J; Aghajanian C; Abu-Rustum N; Varghese A; O'Reilly EM; Morris M; Abida W; Walsh M; Drilon A; Jayakumaran G; Zehir A; Ladanyi M; Ceyhan-Birsoy O; Solit DB; Schultz N; Berger MF; Mandelker D; Diaz LA; Offit K; Robson ME
    J Clin Oncol; 2021 Aug; 39(24):2698-2709. PubMed ID: 34133209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Present status of germline findings in precision medicine for Japanese cancer patients: issues in the current system.
    Higashigawa S; Matsubayashi H; Kiyozumi Y; Kado N; Nishimura S; Oishi T; Sugino T; Fushiki K; Shirasu H; Yasui H; Mamesaya N; Fukuzaki N; Kunitomo K; Horiuchi Y; Kenmotsu H; Serizawa M
    Jpn J Clin Oncol; 2022 May; 52(6):599-608. PubMed ID: 35411369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Germline Analysis from Tumor-Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings.
    Seifert BA; O'Daniel JM; Amin K; Marchuk DS; Patel NM; Parker JS; Hoyle AP; Mose LE; Marron A; Hayward MC; Bizon C; Wilhelmsen KC; Evans JP; Earp HS; Sharpless NE; Hayes DN; Berg JS
    Clin Cancer Res; 2016 Aug; 22(16):4087-4094. PubMed ID: 27083775
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients.
    Zhong X; Dong Z; Dong H; Li J; Peng Z; Deng L; Zhu X; Sun Y; Lu X; Shen F; Su X; Zhang L; Gu Y; Zheng H
    PLoS One; 2016; 11(6):e0156789. PubMed ID: 27257965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA.
    Schrader KA; Cheng DT; Joseph V; Prasad M; Walsh M; Zehir A; Ni A; Thomas T; Benayed R; Ashraf A; Lincoln A; Arcila M; Stadler Z; Solit D; Hyman DM; Zhang L; Klimstra D; Ladanyi M; Offit K; Berger M; Robson M
    JAMA Oncol; 2016 Jan; 2(1):104-11. PubMed ID: 26556299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.
    Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
    Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer.
    Ku GY; Kemel Y; Maron SB; Chou JF; Ravichandran V; Shameer Z; Maio A; Won ES; Kelsen DP; Ilson DH; Capanu M; Strong VE; Molena D; Sihag S; Jones DR; Coit DG; Tuvy Y; Cowie K; Solit DB; Schultz N; Hechtman JF; Offit K; Joseph V; Mandelker D; Janjigian YY; Stadler ZK
    JAMA Netw Open; 2021 Jul; 4(7):e2114753. PubMed ID: 34251444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Using next-generation sequencing (NGS) platform to diagnose pathogenic germline BRCA1/2 mutations from archival tumor specimens.
    Ong PY; Poon SL; Tan KT; Putti TC; Ow SGW; Chen SJ; Chen CH; Lee SC
    Gynecol Oncol; 2019 Nov; 155(2):275-279. PubMed ID: 31481248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
    Penkert J; Schmidt G; Hofmann W; Schubert S; Schieck M; Auber B; Ripperger T; Hackmann K; Sturm M; Prokisch H; Hille-Betz U; Mark D; Illig T; Schlegelberger B; Steinemann D
    Breast Cancer Res; 2018 Aug; 20(1):87. PubMed ID: 30086788
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).
    Hauke J; Hahnen E; Schneider S; Reuss A; Richters L; Kommoss S; Heimbach A; Marmé F; Schmidt S; Prieske K; Gevensleben H; Burges A; Borde J; De Gregorio N; Nürnberg P; El-Balat A; Thiele H; Hilpert F; Altmüller J; Meier W; Dietrich D; Kimmig R; Schoemig-Markiefka B; Kast K; Braicu E; Baumann K; Jackisch C; Park-Simon TW; Ernst C; Hanker L; Pfisterer J; Schnelzer A; du Bois A; Schmutzler RK; Harter P
    J Med Genet; 2019 Sep; 56(9):574-580. PubMed ID: 30979843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A substantial proportion of apparently heterozygous TP53 pathogenic variants detected with a next-generation sequencing hereditary pan-cancer panel are acquired somatically.
    Coffee B; Cox HC; Bernhisel R; Manley S; Bowles K; Roa BB; Mancini-DiNardo D
    Hum Mutat; 2020 Jan; 41(1):203-211. PubMed ID: 31490007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comprehensive Cancer-Predisposition Gene Testing in an Adult Multiple Primary Tumor Series Shows a Broad Range of Deleterious Variants and Atypical Tumor Phenotypes.
    Whitworth J; Smith PS; Martin JE; West H; Luchetti A; Rodger F; Clark G; Carss K; Stephens J; Stirrups K; Penkett C; Mapeta R; Ashford S; Megy K; Shakeel H; Ahmed M; Adlard J; Barwell J; Brewer C; Casey RT; Armstrong R; Cole T; Evans DG; Fostira F; Greenhalgh L; Hanson H; Henderson A; Hoffman J; Izatt L; Kumar A; Kwong A; Lalloo F; Ong KR; Paterson J; Park SM; Chen-Shtoyerman R; Searle C; Side L; Skytte AB; Snape K; Woodward ER; ; Tischkowitz MD; Maher ER
    Am J Hum Genet; 2018 Jul; 103(1):3-18. PubMed ID: 29909963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.